Potassium-Competitive Acid Blockers for Barrett's Esophagus

SK
SE
Overseen BySusan E Moist, MPH
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: University of North Carolina, Chapel Hill
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a research study to look at how a new medication compares to standard treatment for reducing acid reflux in patients with Barrett's Esophagus. The study drug is Vonoprazan. This is a pill that is not yet FDA-approved for this purpose in this patient population.

The participants will first continue their current acid-reducing medicine (PPI) once a day for at least 7 days. After that, they will have a test to measure acid levels in their esophagus (food tube) while still taking the PPI medication. After this test, they will stop their current PPI medication and start taking the study drug, Vonoprazan, once a day for 7-28 days. They will then have a second acid test while on the study drug (Vonoprazan).

Before each test, the participants will complete a short questionnaire about their symptoms. The study team will collect their health history, including medical conditions and current medications. After they finish the study drug, they will have a follow-up visit in about 30 days. The participation in the study will then end.

Who Is on the Research Team?

NS

Nicholas Shaheen, MD, MPH

Principal Investigator

UNC Chapel Hill

Are You a Good Fit for This Trial?

Inclusion Criteria

I have had intestinal metaplasia without dysplasia in the last 3 years.
Able to read and understand English and provide written informed consent
Willing to follow lifestyle recommendations as outlined in protocol section 5.3
See 6 more

Exclusion Criteria

I have a bleeding disorder or cannot stop taking blood thinners.
I have a condition that prevents me from safely having a 24-hour pH test through my nose.
Individuals with implanted devices like pacemakers or defibrillators
See 9 more

What Are the Treatments Tested in This Trial?

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Proton Pump Inhibitors (PPI) to Potassium-Competitive Acid Blockers (PCABs)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of North Carolina, Chapel Hill

Lead Sponsor

Trials
1,588
Recruited
4,364,000+

Phathom Pharmaceuticals, Inc.

Industry Sponsor

Trials
14
Recruited
4,400+